Stent Optimization Using Optical Coherence Tomography and Its Prognostic Implications After Percutaneous Coronary Intervention.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
03 05 2022
Historique:
pubmed: 27 4 2022
medline: 6 5 2022
entrez: 26 4 2022
Statut: ppublish

Résumé

Background Stent underexpansion has been known to be associated with worse outcomes. We sought to define optical coherence tomography assessed optimal stent expansion index (SEI), which associates with lower incidence of follow-up major adverse cardiac events (MACEs). Methods and Results A total of 315 patients (involving 370 lesions) who underwent optical coherence tomography-aided coronary stenting were retrospectively included. SEI was calculated separately for equal halves of each stented segment using minimum stent area/mean reference lumen area ([proximal reference area+distal reference area]/2). The smaller of the 2 was considered to be the SEI of that case. Follow-up MACE was defined as a composite of all-cause death, myocardial infarction, stent thrombosis, and target lesion revascularization. Average minimum stent area was 6.02 (interquartile range, 4.65-7.92) mm

Identifiants

pubmed: 35470682
doi: 10.1161/JAHA.121.023493
pmc: PMC9238610
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e023493

Références

Circ Cardiovasc Interv. 2019 Oct;12(10):e008434
pubmed: 31553205
JACC Cardiovasc Imaging. 2015 Nov;8(11):1297-305
pubmed: 26563859
Eur Heart J. 2006 Jun;27(11):1305-10
pubmed: 16682378
J Am Coll Cardiol. 2020 Dec 1;76(22):2635-2646
pubmed: 33069849
Circulation. 1988 Aug;78(2):486-502
pubmed: 2969312
Lancet. 2016 Nov 26;388(10060):2618-2628
pubmed: 27806900
J Am Coll Cardiol. 2005 Apr 5;45(7):995-8
pubmed: 15808753
Circulation. 2016 Sep 27;134(13):906-17
pubmed: 27573032
EuroIntervention. 2018 Aug 20;14(6):656-677
pubmed: 29939149
Circulation. 2007 May 1;115(17):2344-51
pubmed: 17470709
JACC Cardiovasc Interv. 2017 Dec 26;10(24):2488-2498
pubmed: 29153502
JACC Cardiovasc Interv. 2011 May;4(5):554-9
pubmed: 21596329
Eur Heart J. 2012 Oct;33(20):2551-67
pubmed: 22922414
Circulation. 1995 Apr 1;91(7):1959-65
pubmed: 7895353

Auteurs

Himanshu Rai (H)

Klinik für Herz- und KreislauferkrankungenDeutsches Herzzentrum MünchenTechnische Universität München Munich Germany.
Cardiovascular Research Institute DublinMater Private Network Dublin Ireland.
School of Pharmacy and Biomolecular Sciences RCSI University of Medicine and Health Sciences Dublin Ireland.

Fiona Harzer (F)

Klinik für Herz- und KreislauferkrankungenDeutsches Herzzentrum MünchenTechnische Universität München Munich Germany.

Tatsuhiko Otsuka (T)

Universitätsklinik für KardiologieInselspital Bern Bern Switzerland.

Youssef S Abdelwahed (YS)

Charité - Universitätsmedizin Berlin Berlin Germany.
DZHK (German Centre for Cardiovascular Research)partner site Berlin Bern Germany.

Paula Antuña (P)

Hospital Universitario de La Princesa and Universidad Autónoma de MadridCIBERCV Madrid Spain.

Florian Blachutzik (F)

Universitätsklinikum Gießen und Marburg Giessen Germany.

Tobias Koppara (T)

Klinikum rechts der Isar Munich Germany.

Lorenz Räber (L)

Universitätsklinik für KardiologieInselspital Bern Bern Switzerland.

David M Leistner (DM)

Charité - Universitätsmedizin Berlin Berlin Germany.
DZHK (German Centre for Cardiovascular Research)partner site Berlin Bern Germany.

Fernando Alfonso (F)

Hospital Universitario de La Princesa and Universidad Autónoma de MadridCIBERCV Madrid Spain.

Holger Nef (H)

Universitätsklinikum Gießen und Marburg Giessen Germany.

Masaru Seguchi (M)

Klinik für Herz- und KreislauferkrankungenDeutsches Herzzentrum MünchenTechnische Universität München Munich Germany.

Alp Aytekin (A)

Klinik für Herz- und KreislauferkrankungenDeutsches Herzzentrum MünchenTechnische Universität München Munich Germany.

Erion Xhepa (E)

Klinik für Herz- und KreislauferkrankungenDeutsches Herzzentrum MünchenTechnische Universität München Munich Germany.

Sebastian Kufner (S)

Klinik für Herz- und KreislauferkrankungenDeutsches Herzzentrum MünchenTechnische Universität München Munich Germany.

Salvatore Cassese (S)

Klinik für Herz- und KreislauferkrankungenDeutsches Herzzentrum MünchenTechnische Universität München Munich Germany.

Karl-Ludwig Laugwitz (KL)

Klinikum rechts der Isar Munich Germany.

Robert A Byrne (RA)

Cardiovascular Research Institute DublinMater Private Network Dublin Ireland.
School of Pharmacy and Biomolecular Sciences RCSI University of Medicine and Health Sciences Dublin Ireland.

Adnan Kastrati (A)

Klinik für Herz- und KreislauferkrankungenDeutsches Herzzentrum MünchenTechnische Universität München Munich Germany.
DZHK (German Centre for Cardiovascular Research) partner site Munich Heart Alliance Munich Germany.

Michael Joner (M)

Klinik für Herz- und KreislauferkrankungenDeutsches Herzzentrum MünchenTechnische Universität München Munich Germany.
DZHK (German Centre for Cardiovascular Research) partner site Munich Heart Alliance Munich Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH